Delta-9-tetrahydrocannabinol and cannabidiol: Separating the chemicals from the “weed,” a pharmacodynamic discussion

Cannabis is being increasingly used as a medical treatment for a variety of illnesses. However, the cannabis plant has more than 70 different phytocannabinoids with potential pharmacologic activity. Two of the most researched phytocannabinoids are delta-9-tetrahydrocannabinol (THC) and cannabidiol (...

Descripción completa

Detalles Bibliográficos
Autores principales: Boggs, Douglas Lee, Peckham, Alyssa, Boggs, Angela A., Ranganathan, Mohini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: College of Psychiatric & Neurologic Pharmacists 2016
Materias:
The Pharmacodynamics of Medications Used in Psychiatric Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007535/
https://www.ncbi.nlm.nih.gov/pubmed/29955482
http://dx.doi.org/10.9740/mhc.2016.11.277
Descripción
Sumario:Cannabis is being increasingly used as a medical treatment for a variety of illnesses. However, the cannabis plant has more than 70 different phytocannabinoids with potential pharmacologic activity. Two of the most researched phytocannabinoids are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Evidence suggests CBD can decrease some of the psychomimetic effects of THC. This has led to the development of a new drug, Nabiximols, for the treatment of moderate to severe spasticity due to multiple sclerosis. A discussion of evidence supporting proposed pharmacodynamic interplay between CBD and THC is presented.

Ejemplares similares